Warsaw-based Britenet Med has been awarded a €1 million grant from the European Institute of Innovation and Expertise (EIT) Well being to advance MoodMon, an AI-driven software designed to enhance the administration and therapy of persistent affective issues.
The funding was a part of EIT Well being’s notable Flagship Name, which helps groundbreaking healthcare improvements throughout Europe.
“Our mission with MoodMon is to remodel the administration of persistent affective issues,” stated Małgorzata Sochacka, MoodMon originator and Product Supervisor at Britenet Med. “By providing a first-in-class answer that leverages goal information for psychological well being monitoring, we purpose to boost affected person outcomes, scale back healthcare prices, and allow professionals to allocate their time extra successfully. The funding and collaboration alternatives supplied by the EIT Well being Flagship Name devoted to the digital transformation of healthcare are essential steps in bringing MoodMon to extra sufferers and healthcare suppliers throughout Europe. However we don’t cease right here . We’re happy to deepen our collaboration by becoming a member of EIT Well being as a accomplice. We’re assured that this can allow us to attach with further distinctive companions throughout Europe, fostering the trade of data and experience to boost the therapy of psychological sickness on a worldwide scale.”
Based in 2006, Britenet is a Polish IT firm specialising in consulting and outsourcing providers, in relation to this they’ve developed the AI-based system MoodMon to assist remedy for affective issues.
MoodMon provides an modern method to monitoring situations like despair and bipolar dysfunction, which impression an estimated 280 million individuals worldwide. Conventional monitoring strategies depend on self-observation and subjective reporting, which frequently fall brief in figuring out refined modifications in psychological states.
MoodMon leverages AI to analyse behavioural information collected through cell gadgets and wearables, enabling real-time detection of temper modifications. Its alert system notifies sufferers, psychiatrists, and caregivers promptly, enhancing therapy outcomes.
Medical trials have demonstrated MoodMon’s accuracy, with a sensitivity fee of 89.5% and specificity of 98.83%.
The challenge is backed by a consortium of establishments throughout Europe, together with Spain’s Fundació de Recerca Clínic Barcelona, Sweden’s Karolinska Institute, and Poland’s Medigent Basis.
The consortium has been established to acquire CE certification, conducting additional medical trials, and exploring the financial advantages MoodMon provides to healthcare programs. The event staff additionally goals to create regulatory frameworks that enable AI-driven gadgets like MoodMon to be up to date with out present process full recertification processes.
EIT Well being’s Flagship Name, designed to handle Europe’s most urgent healthcare challenges, highlights the significance of collaborative innovation.
“Our Flagship Calls are about catalysing collaborations that may make an actual distinction in European healthcare,” stated Joanna Broy, EIT Well being InnoStars Lead for Poland. “MoodMon is a chief instance of what might be achieved when modern corporations like Britenet Med come along with main establishments to handle main well being challenges. This challenge showcases the ability of cross-border partnerships in growing options that aren’t solely modern but additionally scalable and impactful. We’re excited to see how MoodMon will enhance the lives of sufferers with affective issues.”
Along with enhancing affected person care, MoodMon may considerably scale back healthcare prices. The annual direct value of the despair therapy ranges from €3k to €5k per affected person and the typical direct value of Bipolar Dysfunction therapy quantities to almost €7k per yr per affected person.
MoodMon’s method may alleviate these monetary pressures by enabling early intervention and higher illness administration.
This funding additionally marks Britenet Med’s deeper integration into EIT Well being’s community, positioning the corporate to collaborate with extra European companions. As EIT Well being has supported over 2,500 startups and introduced 113 healthcare options to market, its function in advancing MoodMon is one other step towards modern options for managing psychological well being.
